Column Group
Latest statistics and disclosures from Column Group's latest quarterly 13F-HR filing:
- Top 5 stock holdings are TNYA, ORIC, Surrozen, RAPT, SGMT, and represent 100.00% of Column Group's stock portfolio.
- Added to shares of these 1 stock: Surrozen.
- Reduced shares in these 1 stock: Ngm Biopharmaceuticals (-$29M).
- Sold out of its position in Ngm Biopharmaceuticals.
- Column Group was a net seller of stock by $-27M.
- Column Group has $71M in assets under management (AUM), dropping by -55.60%.
- Central Index Key (CIK): 0001833486
Tip: Access up to 7 years of quarterly data
Positions held by Column Group consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Column Group
Column Group holds 6 positions in its portfolio as reported in the June 2024 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Tenaya Therapeutics (TNYA) | 40.9 | $29M | 9.4M | 3.10 |
|
|
Oric Pharmaceuticals (ORIC) | 35.1 | $25M | 3.5M | 7.07 |
|
|
Surrozen | 12.4 | $8.9M | +31% | 810k | 10.95 |
|
Rapt Therapeutics (RAPT) | 11.5 | $8.2M | 2.7M | 3.05 |
|
|
Sagimet Biosciences Inc-a (SGMT) | 0.1 | $59k | 17k | 3.42 |
|
|
Revolution Medicines (RVMD) | 0.0 | $1.8k | 46.00 | 38.80 |
|
Past Filings by Column Group
SEC 13F filings are viewable for Column Group going back to 2020
- Column Group 2024 Q2 filed Aug. 15, 2024
- Column Group 2024 Q1 filed May 15, 2024
- Column Group 2023 Q4 filed Feb. 9, 2024
- Column Group 2023 Q3 filed Nov. 13, 2023
- Column Group 2023 Q2 filed July 24, 2023
- Column Group 2023 Q1 filed May 15, 2023
- Column Group 2022 Q4 filed Feb. 13, 2023
- Column Group 2022 Q3 filed Nov. 14, 2022
- Column Group 2022 Q2 filed Aug. 12, 2022
- Column Group 2022 Q1 filed May 16, 2022
- Column Group 2021 Q4 filed Feb. 11, 2022
- Column Group 2021 Q3 filed Nov. 12, 2021
- Column Group 2021 Q2 filed Aug. 16, 2021
- Column Group 2021 Q1 filed May 17, 2021
- Column Group 2020 Q4 filed Feb. 16, 2021